One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient

doi:10.19803/j.1672-8629.20240468

Abstract

Abstract: Objective To explore the clinical characteristics and mechanism of secondary amenorrhea caused by thalidomide in a β-thalassemia patient. Methods Secondary amenorrhea caused by thalidomide in a β-thalassemia patient was analyzed, while the manifestations and pathogenesis were summarized based on literature review. Results The patient developed amenorrhea after 5 months of thalidomide treatment. Four months later, spontaneous menses returned and her hormonal profile returned to normal. The adverse reaction was believed to have been caused by thalidomide. Conclusion Thalidomide can cause hypergonadotropin amenorrhea, so clinicians should be alert to the risk during treatment.

Key words: thalidomide, adverse drug reaction, secondary amenorrhea, menstruation, anemia, thalassemia

CLC Number:

R973
R994.11

YIN Chunyan, KONG Wenqiang, YANG Kun. One case of secondary amenorrhea caused by thalidomide tablets in a β-thalassemia patient[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1181-1183.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20240468

https://zgywjj.magtechjournal.com/EN/Y2024/V21/I10/1181

References

[1] AMARE GG, MEHARIE BG, BELAYNEH YM.A drug repositioning success: the repositioned therapeutic applications and mechanisms of action of thalidomide[J]. Journal of Oncology Pharmacy Practice, 2021, 27(3): 673-678.
[2] VARGESSON N, HOOPER G, LAM SW.Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations[J]. The Journal of Hand Surgery, 2023, 48E(8): 699-709.
[3] ZHANG C, YU Z, GAO S, et al.Efficacy and safety of thalidomide in children with monogenic autoinflammatory diseases: a single-center, real-world-evidence study[J]. Pediatric Rheumatology Online Journal, 2023, 21(1): 124.
[4] DSOUZA NN, ALAMPADY V, BABY K, et al.Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis[J]. Inflammopharmacology, 2023, 31(3): 1167-1182.
[5] EATMANN AI, HAMOUDA E, HAMOUDA H, et al.Potential use of thalidomide in glioblastoma treatment: an updated brief overview[J]. Metabolites, 2023, 13(4): 543.
[6] FOONG WC, LOH CK, HO JJ, et al. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias[J]. The Cochrane Database of Systematic Reviews, 2023, 1: CD013767.
[7] YANG K, LIU X, PENG W, et al.Effects of Thalidomide on erythropoiesis and iron homeostasis in transfusion-dependent beta-thalassemia[J]. Mediterranean Journal of Hematology and Infectious Diseases, 2024, 16: e2024001.
[8] CHEN JM, ZHU WJ, LIU J, et al.Safety and efficacy of thalidomide in patients with transfusion-dependent beta-thalassemia: a randomized clinical trial[J]. Signal Transduction and Targeted Therapy, 2021, 6(1): 405.
[9] YANG K, WU Y, ZHOU Y, et al.Thalidomide for patients with beta-thalassemia: a multicenter experience[J]. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12: e2020021.
[10] JIAN X, LIU X, PENG W, et al.Long-term efficacy and safety of thalidomide treatment in children with beta-thalassemia major[J]. Pediatric Blood Cancer, 2023, 70(9): e30391.
[11] ALI Z, ISMAIL M, REHMAN IU, et al.Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent beta-thalassemia: results from Thal-Thalido study[J]. Scientific Reports, 2023, 13(1): 13592
[12] LI X, HU S, LIU Y, et al.Efficacy of thalidomide treatment in children with transfusion dependent beta-thalassemia: a retrospective clinical study[J]. Frontiers in Pharmacology, 2021, 12: 722502.
[13] PULIDO-PEREZ A, LAZARO-OCHAITA P, SUAREZ-FERNANDEZ R.Amenorrhea during thalidomide treatment: an unusual cause of ovarian failure?[J]. Medicina Clinica, 2017, 149(3): 135-136.
[14] ORDI J, CORTES F, MARTINEZ N, et al.Thalidomide induces amenorrhea in patients with lupus disease[J]. Arthritis & Rheumatology, 1998, 41(12): 2273-2275.
[15] LI JB, CHI Q, LIU PC, et al.Evaluation of reproductive system safety of thalidomide in 214 women of childbearing age with rheumatic diseases[J]. Chinese Journal of New Drugs(中国新药杂志), 2023, 32(22): 2270-2274.
[16] SINGHA A, MUKHOPADHYAY P, GHOSH S. Thalidomide-induced primary amenorrhea in a patient with hbe/beta-thalassemia[J]. JCEM Case Reports, 2023, 1(3): luad057.
[17] YU Y, YANG K.Secondary amenorrhea in a beta-thalassemia major patient treated with thalidomide[J]. Pediatric Blood Cancer, 2024, 71(6): e30982.
[18] SILVA JRV, LIMA FEO, SOUZA ALP, et al.Interleukin-1beta and TNF-alpha systems in ovarian follicles and their roles during follicular development, oocyte maturation and ovulation[J]. Zygote, 2020, 28(4): 1-8.
[19] MEIROW D, LEWIS H, NUGENT D, et al.Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool[J]. Human Reproduction, 1999, 14(7): 1903-1907.
[20] RONESS H, KALICH-PHILOSOPH L, MEIROW D.Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents[J]. Human Reproduction Update, 2014, 20(5): 759-774.
[21] OCHALSKI ME, ORWIG KE.Thalidomide reduces ovarian microvasculature and protects ovarian follicles from chemotherapy damage[J]. Fertility & Sterility, 2011, 96(3): S33.